Comparable stake leader
MORGAN STANLEY
SEC ownership of X4 Pharmaceuticals, Inc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001501697.
Disclosed value leader
MORGAN STANLEY
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- XFOR on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
MORGAN STANLEY
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
MORGAN STANLEY
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001501697
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of X4 Pharmaceuticals, Inc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MORGAN STANLEY
Disclosed value leader
MORGAN STANLEY
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: MORGAN STANLEY
Showing 1-8 of 50 holder rows.
Quick read
MORGAN STANLEY leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MORGAN STANLEY's linked filing trail.
Comparable ownership
Top 5
MORGAN STANLEY
10%
Empery Asset Management, LP
10%
Deep Track Capital, LP
10%
Coastlands Capital LP
10%
FMR LLC
9.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MORGAN STANLEY |
13F
13D/G
Company
|
10%
from 13D/G
|
$39,098,676
9,466,992 shares
|
— | 31 Mar 2026 |
| Empery Asset Management, LP |
13F
13D/G
Company
|
10%
from 13D/G
|
$36,939,207
8,944,118 shares
|
— | 31 Mar 2026 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
10%
from 13D/G
|
$26,182,280
6,339,535 shares
|
— | 31 Mar 2026 |
| Coastlands Capital LP |
13D/G
|
10%
|
$7,773,911
2,491,638 shares
|
+$37,418 | 03 Oct 2025 |
| FMR LLC |
13D/G
13F
Company
|
9.7%
|
$33,996,400
8,499,100 shares
|
$0 | 31 Oct 2025 |
| Saturn V Capital Management LP |
13F
13D/G
Company
|
7.4%
from 13D/G
|
$26,665,948
6,456,646 shares
|
— | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
Company
|
7.3%
from 13D/G
|
$27,826,486
6,737,648 shares
|
— | 31 Mar 2026 |
| Growth Equity Opportunities 18 VGE, LLC |
13D/G
|
6.2%
|
$17,496,802
5,057,610 shares
|
+$9,734,867 | 27 Oct 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$140,749.
Buys
$249,997
Insiders: 1
Sells
$109,249
Insiders: 1
Net
+$140,749
Shares: +60,702
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 86,206
Shares: 25,504
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 25,504 | $0 | $109,249 | -$109,249 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 86,206 | 0 | $249,997 | $0 | +$249,997 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to X4 Pharmaceuticals, Inc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Paula Ragan
Net 12M change
+$140,748
Latest report
01 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Paula Ragan | President and CEO, Director | $1,515,173 | Mixed | 12 Feb 2025 | ||
| Adam R. Craig | Executive Chairman, Director | $1,090,652 | +$249,997 | +30% | Filing P/S | 29 Oct 2025 |
| David Kirske | Chief Financial Officer | $715,302 | -$109,249 | -13% | Filing P/S | 30 Jun 2026 |
| John Volpone | President | $550,773 | Mixed | 29 Oct 2025 | ||
| Mary DiBiase | Chief Operating Officer | $518,005 | Mixed | 12 Feb 2025 | ||
| Christophe Arbet-Engels | Chief Medical Officer | $392,350 | Mixed | 12 Feb 2025 | ||
| Adam S. Mostafa | Chief Financial Officer | $385,900 | Mixed | 12 Feb 2025 | ||
| Arthur Taveras | Chief Scientific Officer | $218,459 | Filing P/S | 04 Oct 2024 | ||
| Derek M. Meisner | Chief Legal Officer | $130,640 | Mixed | 17 Aug 2022 | ||
| Diego Cadavid | Chief Medical Officer | $93,696 | Mixed | 01 Mar 2022 | ||
| Alison Frances Lawton | Director | $85,241 | Mixed | 10 Jun 2024 | ||
| William Aliski | Director | $85,241 | Mixed | 10 Jun 2024 | ||
| Mark Baldry | Chief Commercial Officer | $62,886 | Mixed | 16 May 2025 | ||
| Natasha Fay Thoren | Chief Legal Officer | $1,797 | Market | 20 May 2025 | ||
| Murray Stewart | Director | $1,497 | Market | 01 Jan 2026 | ||
| Keith Woods | Director | $1,140 | Market | 09 Jun 2025 | ||
| Michael S. Wyzga | Director | $1,055 | Market | 01 Jan 2026 | ||
| David W. J. Mcgirr | Director | $897 | Market | 09 Jun 2025 | ||
| Francoise de Craecker | Director | $897 | Market | 01 Jan 2026 | ||
| Gary Bridger | Director | $897 | Market | 01 Jan 2026 |
Recent insider transactions for X4 Pharmaceuticals, Inc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kelly Gold | XFOR | Stock Option (right to buy) | Award | 110,000 | 110,000 | 01 Jul 2026 | Direct | |||
| David Kirske | XFOR | Common Stock | Sale | -4.85% | $36,428 | $4.26 | -8,543 | 167,750 | 30 Jun 2026 | Direct |
| David Kirske | XFOR | Common Stock | Sale | -8.78% | $72,820 | $4.29 | -16,961 | 176,293 | 12 May 2026 | Direct |
| Gary Bridger | XFOR | Stock Option (right to buy) | Award | 110,000 | 0 | 01 Jan 2026 | Direct | |||
| Francoise de Craecker | XFOR | Stock Option (right to buy) | Award | 110,000 | 0 | 01 Jan 2026 | Direct | |||
| Michael S. Wyzga | XFOR | Stock Option (right to buy) | Award | 110,000 | 0 | 01 Jan 2026 | Direct | |||
| Murray Stewart | XFOR | Stock Option (right to buy) | Award | 110,000 | 0 | 01 Jan 2026 | Direct | |||
| Adam R. Craig | XFOR | Stock Option (right to buy) | Award | 2,329,154 | 2,329,154 | 29 Oct 2025 | Direct | |||
| John Volpone | XFOR | Stock Option (right to buy) | Award | 2,329,154 | 2,329,154 | 29 Oct 2025 | Direct | |||
| David Kirske | XFOR | Stock Option (right to buy) | Award | 1,552,769 | 1,552,769 | 29 Oct 2025 | Direct | |||
| Adam R. Craig | XFOR | Common Stock | Purchase | 29.7% | $249,997 | $2.90 | 86,206 | 376,087 | 23 Oct 2025 | Direct |
| John Volpone | XFOR | Common Stock | Award | 289,881 | 289,881 | 14 Aug 2025 | Direct | |||
| John Volpone | XFOR | Stock Option (right to buy) | Award | 529,201 | 529,201 | 14 Aug 2025 | Direct | |||
| Adam R. Craig | XFOR | Common Stock | Award | 289,881 | 289,881 | 14 Aug 2025 | Direct | |||
| Adam R. Craig | XFOR | Stock Option (right to buy) | Award | 529,201 | 529,201 | 14 Aug 2025 | Direct | |||
| David Kirske | XFOR | Common Stock | Award | 193,254 | 193,254 | 14 Aug 2025 | Direct | |||
| David Kirske | XFOR | Stock Option (right to buy) | Award | 352,800 | 352,800 | 14 Aug 2025 | Direct | |||
| John Volpone | XFOR | Stock Option (right to buy) | Award | 1,609,873 | 1,609,873 | 12 Aug 2025 | Direct | |||
| Adam R. Craig | XFOR | Stock Option (right to buy) | Award | 1,609,873 | 1,609,873 | 12 Aug 2025 | Direct | |||
| David Kirske | XFOR | Stock Option (right to buy) | Award | 1,073,249 | 1,073,249 | 12 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.